ClinicalTrials.gg
Active, not recruitingNCT06238622FIBRONEER™-ONUpdated Nov 12, 2026

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

A Phase 3 interventional study of Nerandomilast in Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis, sponsored by Boehringer Ingelheim. Active, not recruiting at 375 sites in 44 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Updated Nov 12, 2026Start date movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,666
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies in Idiopathic Pulmonary Fibrosis by Boehringer Ingelheim — 1 open to participants now, 3 under way, 1 of them phase 3. Idiopathic Pulmonary Fibrosis · Boehringer Ingelheim.

Enrollment
Largest of 18
1,666 · median 109
Started
2024
with 4 others
Phase 3
5 of 36
none open now
Registered
29th of 36
by date

Among the 36 studies in Idiopathic Pulmonary Fibrosis by Boehringer Ingelheim, this one has the largest enrollment of the 18 interventional ones that give a count, is one of 5 that started in 2024, is one of 5 in phase 3, and was the 29th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

1 of the 36 studies in Idiopathic Pulmonary Fibrosis by Boehringer Ingelheim is open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Idiopathic Pulmonary Fibrosis by Boehringer Ingelheim, or all of them as a file.
02

Study summary

This study is open to people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). They can only take part if they have completed treatment in a previous study with a medicine called nerandomilast or BI 1015550.

The goal of this study is to find out how well people with pulmonary fibrosis tolerate long- term treatment with nerandomilast. The study also tests whether nerandomilast improves lung function and prolongs the time until symptoms get worse, participants need to go to the hospital, or die.

Every participant takes nerandomilast as tablets for up to 1 year and 10 months. The participants may also continue their regular treatment for pulmonary fibrosis during the study.

Participants visit their doctors regularly. During these visits, the doctors collect information on any health problems of the participants. Participants also regularly do lung function tests.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis
  • Progressive Pulmonary Fibrosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who completed treatment in the parent trials (1305-0014, 1305-0023, or 1305-0035) without prematurely discontinuing treatment permanently according to protocol (i.e. completed treatment with or without temporary treatment interruption)
  2. Signed and dated written in accordance with ICH-GCP and local legislation prior to admission to the trial
  3. Women of (WOCBP) must be ready and able to use highly effective methods of per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. WOCBP taking oral contraceptives (OCs) also have to ensure the use of one barrier method during sexual intercourse with their partner, e.g., condom to account for the risk of potentially reduced efficacy of the OCs in the event of severe vomiting and diarrhoea. For France, fertile males must be ready and able to use acceptable methods of birth control

Exclusion criteria

Exclusion Criteria:

  1. Any disease that may put the patient at risk when participating in this trial at investigator's discretion.
  2. Patient exhibits suicidality, in the clinical judgment of the investigator or according to the following criteria at Visit 1:

    • any suicidal behaviour (i.e. actual attempt, interrupted attempt, aborted attempt, or preparatory acts or behaviour)
    • any suicidal ideation of type 4 or 5 in the Columbia-Suicide Severity Rating Scale (C-SSRS) (i.e. active suicidal thought with intent but without specific plan, or active suicidal thought with plan and intent)
  3. Patients with severe depression at investigator's discretion or a Hospital Anxiety and Depression Scale (HADS) subscore >14 at Visit 1.
  4. An occurrence of malignant neoplasm other than appropriately treated basal cell carcinoma or in situ squamous cell carcinoma of the skin or in situ carcinoma of uterine cervix at Visit 1.
  5. Patient will undergo lung transplantation, with an assigned date of surgery.
  6. Patients with a (BMI) \<18.5 kg/m² that experienced an additional, unexplained and clinically significant (>10%) weight loss during the parent trial
  7. At Visit 1, patients with ongoing Adverse Event of Special Interest (AESI), except for latent tuberculosis (suspected vasculitis, Drug Induced Liver Injury (DILI), severe infections) that led to temporary treatment interruption in the parent trial
  8. Patients who must or wish to take restricted medications or any drug considered likely to interfere with the safe conduct of the trial.

Further exclusion criteria apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,666 participants (actual)

Study arms

  • Experimental
    BI 1015550 treatment group

    Drug: Nerandomilast

Interventions

  • Nerandomilast

    Also known as: BI 1015550, JASCAYD®

06

What researchers measure

Primary outcomes

  1. Occurrence of any adverse event over the course of the extension trial (yes/no) i.e. up until the follow-up/end of study visit planned at the latest at week 99

    Time frame: Up to 99 weeks and 3 days

Secondary outcomes

  1. Absolute change from baseline in Forced vital capacity (FVC) (mL) over time

    Time frame: Up to 98 weeks

  2. Absolute change from baseline in % predicted in Forced vital capacity (FVC) over time

    Time frame: Up to 98 weeks

  3. Time to absolute decline in FVC % predicted of >10% from baseline over the duration of the trial

    Time frame: Up to 98 weeks

  4. Time to first acute Idiopathic Pulmonary Fibrosis/Progressive Pulmonary Fibrosis (IPF/PPF) exacerbation, first hospitalisation for respiratory cause, or death (whichever occurs first) over the duration of the trial

    Time frame: Up to 98 weeks

  5. Time to first acute Idiopathic Pulmonary Fibrosis/Progressive Pulmonary Fibrosis (IPF/PPF) exacerbation or death over the duration of the trial

    Time frame: Up to 98 weeks

  6. Time to hospitalisation for respiratory cause or death over the duration of the trial

    Time frame: Up to 98 weeks

  7. Time to absolute decline in Forced vital capacity (FVC) % predicted of >10% from baseline or death over the duration of the trial

    Time frame: Up to 98 weeks

  8. Time to relative decline in Forced vital capacity (FVC) % predicted of >10% from baseline or death over the duration of the trial

    Time frame: Up to 98 weeks

07

Study locations

375 sites

Showing the first 100 of 375 sites across 44 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Wuyts WA, Richeldi L, Assassi S, Azuma A, Cottin V, Hoffmann-Vold AM, Kreuter M, Oldham JM, Martinez FJ, Valenzuela C, Wijsenbeek MS, Kanakapura M, James A, Weimann G, Drzewuski C, Coeck C, Maher TM. Design of an open-label extension trial of nerandomilast (BI 1015550) in patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis (FIBRONEER-ON). BMC Pulm Med. 2025 Dec 4;26(1):10. doi: 10.1186/s12890-025-03973-7. PubMed 41345848 ↗

Related links

Individual participant data

Plan to share: Yes — Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.

Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Data sharing details ↗ · www.clinicalstudies.boehringer-ingelheim.com

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Apr 2027, 31 months after the start.

Of 24 phase 3 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 60. This study's planned 31 months is below that.

Start moved once since we started tracking on Sep 25, 2026: May 2024 → Sep 2024, on Oct 14, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2024
First posted
Feb 2, 2024
StartActual
Sep 26, 2024was May 2024
Primary completionEst.
Apr 28, 2027
CompletionEst.
May 7, 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
8 sites added, 6 sites removed
Show 8 added (2 Brazil, 2 Taiwan, 2 Spain, 1 United States, 1 France)
  • SAPIENS - Instituto de Estudos e Pesquisa Clinica · Curitiba, Brazil
  • Hospital das Clinicas da Faculdade de Medicina da USP · São Paulo, Brazil
  • Kaohsiung Medical University Chung-Ho Memorial Hospital · Kaohsiung City, Taiwan
  • New York Presbyterian Hospital -Columbia University · New York, United States
  • HOP Haut-Leveque · Pessac, France
  • China Medical University Hospital · Taichung, Taiwan
  • Hospital Universitari Son Espases · Palma de Mallorca, Spain
  • Hospital Universitario Virgen del Rocio · Seville, Spain
Show 6 removed
  • SAPIENS - Instituto de Estudos e Pesquisa Clínica · Curitiba, Brazil
  • Hospital das Clínicas da Faculdade de Medicina da USP · São Paulo, Brazil
  • Columbia University Medical Center-New York Presbyterian Hospital · New York, United States
  • HOP Haut-Lévêque · Pessac, France
  • Hospital Son Espases · Palma de Mallorca, Spain
  • Hospital Virgen del Rocio · Seville, Spain
across 4 updates, Sep 30, 2026 – Nov 12, 2026
Start date
May 6, 2024→Sep 26, 2024
Oct 14, 2026
Study completion
May 5, 2027→May 7, 2027
Sep 30, 2026
Show all 4 updates
  1. Nov 12, 2026
    2 sites added, 2 sites removed
    Show 2 added (2 Spain)
    • Hospital Universitari Son Espases · Palma de Mallorca, Spain
    • Hospital Universitario Virgen del Rocio · Seville, Spain
    Show 2 removed
    • Hospital Son Espases · Palma de Mallorca, Spain
    • Hospital Virgen del Rocio · Seville, Spain
    + 1 other change: verification date
  2. Oct 28, 2026
    3 sites added, 2 sites removed
    Show 3 added (1 United States, 1 France, 1 Taiwan)
    • New York Presbyterian Hospital -Columbia University · New York, United States
    • HOP Haut-Leveque · Pessac, France
    • China Medical University Hospital · Taichung, Taiwan
    Show 2 removed
    • Columbia University Medical Center-New York Presbyterian Hospital · New York, United States
    • HOP Haut-Lévêque · Pessac, France
  3. Oct 14, 2026
    2 sites added, 1 site removed
    Show 2 added (1 Brazil, 1 Taiwan)
    • Hospital das Clinicas da Faculdade de Medicina da USP · São Paulo, Brazil
    • Kaohsiung Medical University Chung-Ho Memorial Hospital · Kaohsiung City, Taiwan
    Show 1 removed
    • Hospital das Clínicas da Faculdade de Medicina da USP · São Paulo, Brazil
    Start date May 6, 2024→Sep 26, 2024
    + 1 other change: verification date
  4. Sep 30, 2026
    1 site added, 1 site removed
    Show site
    • SAPIENS - Instituto de Estudos e Pesquisa Clinica · Curitiba, Brazil
    Show 1 removed
    • SAPIENS - Instituto de Estudos e Pesquisa Clínica · Curitiba, Brazil
    Study completion May 5, 2027→May 7, 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06238622
Responsible party
Sponsor
First posted
Feb 2, 2024
Start date
Sep 26, 2024
Primary completion
Apr 28, 2027 (estimated)
Completion
May 7, 2027 (estimated)
Last update
Nov 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nerandomilast

Start the discussion